Wall Street analysts’ outlook for Veracyte Inc. (VCYT)

Veracyte Inc. (NASDAQ: VCYT) stock fell -5.70% on Friday to $17.05 against a previous-day closing price of $18.08. With 1.35 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.94 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $18.26 whereas the lowest price it dropped to was $16.99. The 52-week range on VCYT shows that it touched its highest point at $54.13 and its lowest point at $14.85 during that stretch. It currently has a 1-year price target of $30.33. Beta for the stock currently stands at 1.18.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VCYT was down-trending over the past week, with a drop of -11.34%, but this was down by -19.50% over a month. Three-month performance dropped to -9.02% while six-month performance fell -39.45%. The stock lost -65.32% in the past year, while it has lost -58.62% so far this year. A look at the trailing 12-month EPS for VCYT yields -0.69 with Next year EPS estimates of -0.65. For the next quarter, that number is -0.25. This implies an EPS growth rate of -69.70% for this year and 19.80% for next year.

Float and Shares Shorts:

At present, 71.48 million VCYT shares are outstanding with a float of 70.86 million shares on hand for trading. On Jul 14, 2022, short shares totaled 3.91 million, which was 5.48% higher than short shares on Jun 14, 2022. In addition to Ms. Bonnie H. Anderson as the firm’s Co-Founder & Exec. Chairwoman, Mr. Marc A. Stapley serves as its CEO & Director.

Institutional Ownership:

Through their ownership of 106.00% of VCYT’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 69.60% of VCYT, in contrast to 35.19% held by mutual funds. Shares owned by individuals account for 17.23%. As the largest shareholder in VCYT with 12.37% of the stake, ARK Investment Management LLC holds 8,856,245 shares worth 8,856,245. A second-largest stockholder of VCYT, The Vanguard Group, Inc., holds 6,587,506 shares, controlling over 9.20% of the firm’s shares. Wellington Management Co. LLP is the third largest shareholder in VCYT, holding 5,851,913 shares or 8.18% stake. With a 6.80% stake in VCYT, the ARK Innovation ETF is the largest stakeholder. A total of 4,864,210 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 5.15% of VCYT stock, is the second-largest Mutual Fund holder. It holds 3,684,096 shares valued at 75.16 million. Nikko AM Global Umbrella Fund – A holds 3.70% of the stake in VCYT, owning 2,645,855 shares worth 53.98 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2022, VCYT reported revenue of $72.86M and operating income of -$9.80M. Over the past year, revenue came in at $268.35M while operating income stood at -$54.99M. It generated -$9.53M net income for the quarter, which came to -$48.65M over the last twelve months. The EBITDA in the recently reported quarter was -$2.72M and diluted EPS was -$0.13. EBITDA for the full year was -$25.43M.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VCYT since 8 analysts follow the stock currently. There are 5 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With VCYT analysts setting a high price target of $35.00 and a low target of $23.00, the average target price over the next 12 months is $30.33. Based on these targets, VCYT could surge 105.28% to reach the target high and rise by 34.9% to reach the target low. Reaching the average price target will result in a growth of 77.89% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. VCYT will report FY 2022 earnings on 02/28/2023. Analysts have provided yearly estimates in a range of -$0.78 being high and -$0.89 being low. For VCYT, this leads to a yearly average estimate of -$0.83. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Veracyte Inc. surprised analysts by $0.09 when it reported -$0.13 EPS against a consensus estimate of -$0.22. The surprise factor in the prior quarter was $0.03. Based on analyst estimates, the high estimate for the next quarter is -$0.23 and the low estimate is -$0.29. The average estimate for the next quarter is thus -$0.26.

Summary of Insider Activity:

Insiders traded VCYT stock several times over the past three months with 8 Buys and 4 Sells. In these transactions, 72,095 shares were bought while 122,945 shares were sold. The number of buy transactions has increased to 32 while that of sell transactions has risen to 31 over the past year. The total number of shares bought during that period was 539,019 while 254,193 shares were sold.

Leave a Comment

Your email address will not be published.